Want to see HK:1548 full AI Analyst Report?
Top Page
Genscript Biotech
(1548)
Select Model
Select Model
Rating:54Neutral
Price Target:
HK$15.00
▲(9.01% Upside)
Action:Reiterated
Date:06/02/26
The score is primarily supported by improved 2025 operating performance and cash flow, but it is held back by highly volatile net income (including a large 2025 net loss), weak price trend versus moving averages, and a negative P/E that reflects ongoing earnings losses.
Positive Factors
Revenue and margin recovery
The company delivered a pronounced operational rebound in 2025 with very strong revenue growth and materially improved gross and EBIT margins. Sustained higher margins and topline expansion support durable cash generation potential and reinvestment capacity over the next 2–6 months.
Negative Factors
Highly volatile net income
Net income has swung sharply year to year, producing a large loss in 2025 after an outsized 2024 profit. This volatility indicates earnings are sensitive to one‑off items or timing, undermining confidence in sustained profitability and predictable shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and margin recovery
The company delivered a pronounced operational rebound in 2025 with very strong revenue growth and materially improved gross and EBIT margins. Sustained higher margins and topline expansion support durable cash generation potential and reinvestment capacity over the next 2–6 months.
Read all positive factors
Genscript Biotech (1548) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$28.78B
Dividend YieldN/A
Average Volume (3M)11.61M
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue Growth60.96%
EPS Growth-117.64%
CountryHK
Employees6,165
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.25
Shares Outstanding2,188,547,400
10 Day Avg. Volume8,707,016
30 Day Avg. Volume11,605,265
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.87
Price to Sales (P/S)3.60
P/FCF Ratio14.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$25.57Price Target Upside85.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$812.30M
Genscript Biotech Business Overview & Revenue Model
Company Description
Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassin...
How the Company Makes Money
GenScript primarily makes money by charging customers (biopharma companies, biotech firms, and research institutions) for outsourced R&D and manufacturing services and for sales of research-use products. Key revenue streams include: (1) Life Scien...
Genscript Biotech Earnings Call Summary
Earnings Call Date:Aug 17, 2025
(Q2-2025)
| Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth across all segments, strong performance of Legend Biotech's CAR-T product, and a robust cash position. However, the Group faced challenges with net losses due to Legend Biotech, temporary impacts on gross margins, and capacity issues in ProBio. Despite these challenges, the positive achievements and growth outweigh the difficulties.Positive Updates
Record Revenue Growth
The Group's revenue increased by 81.9% year-over-year to approximately USD 519 million. All three segments achieved growth, with GenScript Life Science growing by 11.3%, ProBio by 511%, and Bestzyme by 8.4%.
Negative Updates
Net Loss Due to Legend Biotech
The Group's net loss was approximately USD 24.5 million, significantly impacted by Legend Biotech's current period loss and the amortization impact of a USD 3.2 billion variation increase when it was deconsolidated in 2024.
Read all updates
Q2-2025 Updates
Positive
Negative
Record Revenue Growth
The Group's revenue increased by 81.9% year-over-year to approximately USD 519 million. All three segments achieved growth, with GenScript Life Science growing by 11.3%, ProBio by 511%, and Bestzyme by 8.4%.
Read all positive updates
Company Guidance
During the 2025 interim results conference call, GenScript provided detailed guidance on their financial and operational performance for the first half of the year and projections for the second half. The company reported an impressive 82% year-over-year revenue growth, with the adjusted profit from continuing operations significantly increasing to approximately USD 180 million. Key highlights included the GenScript Life Science business achieving an 11.3% revenue increase to USD 248 million, and ProBio exhibiting a robust 511% growth to USD 247 million. Bestzyme also experienced a revenue rise of 8.4% to USD 28.3 million. Legend Biotech's CAR-T product, CARVYKTI, treated over 7,500 patients and saw a 136% increase in net trade sales to USD 439 million. GenScript forecasts continued growth, with GenScript Life Science's full-year revenue expected to increase by 13% to 15% and anticipates ProBio to recognize additional milestone payments in the second half. The company maintains a strong cash position of USD 970 million, supporting global expansion and R&D initiatives. Additionally, GenScript remains committed to advancing ESG initiatives, earning a silver medal from EcoVadis and an AA rating from MSCI ESG, reflecting their dedication to sustainability and governance.Genscript Biotech Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
72
Positive
Cash Flow
60
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 959.53M | 594.49M | 839.53M | 625.70M | 490.10M |
| Gross Profit | 553.20M | 272.13M | 270.63M | 304.08M | 282.52M |
| EBITDA | 317.61M | 70.43M | -249.42M | -389.04M | -477.27M |
| Net Income | -532.83M | 2.96B | -95.48M | -226.85M | -358.71M |
Balance Sheet | |||||
| Total Assets | 4.85B | 5.28B | 3.39B | 2.55B | 2.23B |
| Cash, Cash Equivalents and Short-Term Investments | 843.01M | 621.18M | 1.93B | 1.46B | 1.41B |
| Total Debt | 258.84M | 723.74M | 416.99M | 349.80M | 156.45M |
| Total Liabilities | 876.30M | 954.91M | 1.34B | 1.18B | 846.17M |
| Stockholders Equity | 3.96B | 4.32B | 1.39B | 1.01B | 1.05B |
Cash Flow | |||||
| Free Cash Flow | 241.69M | -72.27M | -444.62M | -336.40M | -269.83M |
| Operating Cash Flow | 325.52M | 75.65M | -286.91M | -120.29M | -136.79M |
| Investing Cash Flow | -171.95M | -1.46B | -357.73M | -443.30M | -212.55M |
| Financing Cash Flow | -144.89M | 66.52M | 1.07B | 419.32M | 902.14M |
Genscript Biotech Technical Analysis
Neutral
13.76
Price Trends
13.16
Positive
12.69
Positive
13.72
Negative
Market Momentum
0.43
Negative
49.96
Neutral
56.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1548, the sentiment is Neutral. The current price of 13.76 is above the 20-day moving average (MA) of 12.99, above the 50-day MA of 13.16, and above the 200-day MA of 13.72, indicating a neutral trend. The MACD of 0.43 indicates Negative momentum. The RSI at 49.96 is Neutral, neither overbought nor oversold. The STOCH value of 56.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1548.
Genscript Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$65.44B | 52.09 | 6.34% | 1.57% | 18.78% | 12.65% | |
64 Neutral | HK$153.23B | 26.90 | 10.64% | ― | 16.79% | 47.14% | |
61 Neutral | HK$67.75B | 36.96 | 11.22% | 1.04% | 16.83% | -8.65% | |
58 Neutral | HK$2.21B | 41.75 | 1.98% | ― | 0.61% | 766.67% | |
58 Neutral | HK$2.52B | 10.60 | 5.57% | ― | -12.90% | 33.65% | |
54 Neutral | HK$28.78B | -6.70 | -12.72% | ― | 60.96% | -117.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1548
Genscript Biotech
13.22
-3.20
-19.49%
HK:2269
Wuxi Biologics (Cayman)
36.98
8.98
32.07%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
23.20
5.01
27.51%
HK:1521
Frontage Holdings Corp.
1.08
-0.27
-20.00%
HK:1873
Viva Biotech Holdings
1.21
-0.31
-20.39%
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
117.20
25.96
28.46%
Genscript Biotech Corporate Events
Genscript Highlights Strong CARVYKTI Sales via Legend Biotech, Urges Investor Caution
Jul 15, 2026
Genscript Biotech announced that its associate Legend Biotech reported preliminary net trade sales of approximately US$657 million for CARVYKTI for the quarter ended 30 June 2026, under a collaboration and license agreement with Janssen Biotech, I...
GenScript Associate Legend Biotech Reports Promising In Vivo CAR-T Data in B-Cell Lymphoma
Jun 14, 2026
GenScript’s associate Legend Biotech has reported first clinical proof-of-concept data for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The dat...
Genscript Biotech Shareholders Approve All Resolutions at 2026 AGM
Jun 5, 2026
Genscript Biotech Corporation reported that all resolutions proposed at its annual general meeting on 5 June 2026 were passed by shareholders by way of poll. All directors attended either in person or via telecommunication, and the company confirm...
Genscript Biotech Grants 14.7 Million RSUs to Strengthen Long-Term Incentives
Jun 4, 2026
Genscript Biotech Corporation is a Cayman Islands–incorporated biotechnology company listed in Hong Kong that focuses on biotechnological research and development services. The group’s operations rely heavily on key scientific talent, ...
Genscript Highlights Legend Biotech’s Early In Vivo CAR-T Data for B-Cell Lymphoma
Jun 2, 2026
Genscript Biotech announced that its associate, Legend Biotech, will present promising preliminary Phase 1 clinical data for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-...
Genscript Highlights Legend Biotech’s New CAR-T Data in Oncology Programs
Jun 1, 2026
Genscript Biotech has announced that its associate Legend Biotech presented first-in-human clinical data for LB2102, an investigational DLL3-targeted CAR-T cell therapy for patients with relapsed or refractory small cell lung cancer and large-cell...
GenScript Associate Legend Biotech to Unveil New CAR-T Data at 2026 ASCO Meeting
May 22, 2026
Legend Biotech, an associate of GenScript Biotech, has announced that it will present new clinical data at the 2026 American Society of Clinical Oncology Annual Meeting, underscoring its ongoing efforts in cutting-edge cancer therapies. The presen...
Genscript flags Legend Biotech Q1 results and cautions investors on risk
May 12, 2026
Genscript Biotech announced that its associate, Legend Biotech Corporation, has filed first-quarter 2026 financial results and business highlights with the U.S. securities regulator, directing investors to consult the official filing for full deta...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.